Literature DB >> 10231037

Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.

A Enskog1, M Henriksson, M Unander, L Nilsson, M Brännström.   

Abstract

OBJECTIVE: To compare patient characteristics and clinical and laboratory parameters in patients in whom ovarian hyperstimulation syndrome (OHSS) develops with those in whom it does not develop.
DESIGN: Prospective cohort study.
SETTING: Reproductive medicine unit at a university medical center. PATIENT(S): All patients undergoing IVF (n = 428) who received controlled ovarian hyperstimulation during a 6-month period. INTERVENTION(S): Prospective data collection. MAIN OUTCOME MEASURE(S): Patient characteristics (age, body mass index, medical history, smoking habits) and clinical and laboratory data obtained during controlled ovarian hyperstimulation were evaluated in patients who had severe OHSS, any degree of OHSS, or a significant risk of OHSS and compared with the remaining populations. RESULT(S): Severe OHSS developed in 18 patients (4.2%) and mild or moderate OHSS developed in 7.3%. As a group, all the patients with OHSS were significantly younger, received lower doses of gonadotropins, had ovaries containing a higher number of total and large follicles, had a higher number of retrieved oocytes, and had a higher pregnancy rate than the patients without OHSS. The patients with severe OHSS also had an increased prevalence of allergy (56% versus 21%) and were more likely to ultimately give birth. CONCLUSION(S): The observed differences may be useful in elucidating the pathophysiology of OHSS and identifying patients who are at increased risk for OHSS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231037     DOI: 10.1016/s0015-0282(99)00090-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  22 in total

1.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

2.  Economic evaluation of infertility treatment for tubal disease.

Authors:  M Granberg; A Strandell; J Thorburn; S Daya; M Wikland
Journal:  J Assist Reprod Genet       Date:  2003-08       Impact factor: 3.412

3.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

4.  Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies.

Authors:  Huilin Tang; Yingying Yan; Tiansheng Wang; Ting Zhang; Weilong Shi; Rong Fan; Yao Yao; Suodi Zhai
Journal:  J Assist Reprod Genet       Date:  2015-10-19       Impact factor: 3.412

Review 5.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Ovarian hyperstimulation syndrome after assisted reproductive technologies: trends, predictors, and pregnancy outcomes.

Authors:  David A Schirmer; Aniket D Kulkarni; Yujia Zhang; Jennifer F Kawwass; Sheree L Boulet; Dmitry M Kissin
Journal:  Fertil Steril       Date:  2020-07-14       Impact factor: 7.329

7.  Ovarian hyperstimulation syndrome: current views on pathophysiology, risk factors, prevention, and management.

Authors:  Michael M Alper; Laura P Smith; Eric Scott Sills
Journal:  J Exp Clin Assist Reprod       Date:  2009-06-10

8.  The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Cristiano Busso; Manuel Fernández-Sánchez; Juan Antonio García-Velasco; José Landeras; Augustín Ballesteros; Elkin Muñoz; Sandra González; Carlos Simón; Joan-Carles Arce; Antonio Pellicer
Journal:  Hum Reprod       Date:  2010-02-06       Impact factor: 6.918

9.  Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Authors:  Ya-Qin Wang; Jin Luo; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jin Yang
Journal:  J Ovarian Res       Date:  2015-09-23       Impact factor: 4.234

10.  Comparison of follicular fluid and serum levels of Inhibin A and Inhibin B with calculated indices used as predictive markers of Ovarian Hyperstimulation Syndrome in IVF patients.

Authors:  Jiri Moos; Karel Rezabek; Vanda Filova; Martina Moosova; Jana Pavelkova; Jana Peknicova
Journal:  Reprod Biol Endocrinol       Date:  2009-08-24       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.